All Stories

  1. Copper-64: An Optimal Radionuclide for the Routine Preparation of PET Imaging Radiotracers from GMP-Lyophilized Gelatin-NOTA-Peptide Kits
  2. Enhancing Cytosolic Internalization of [177Lu]Lu–iPSMA in Prostate Cancer Cells: The Effect of Conjugating a GRP78 Inhibitor to the Radiotherapeutic Molecule
  3. Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview
  4. Charge Transfer Reactions (PDT Reaction I) Induced at 1064 nm (NIR-II) between Rhodamines and Folic Acid as the Basis for Biphotonic Photodynamic Therapy
  5. Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose
  6. Synthesis and Evaluation of [18F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [177Lu]Lu-DOTA-iPD-L1
  7. Enhancing photodynamic and radionuclide therapy by small interfering RNA (siRNA)-RAD51 transfection via self-emulsifying delivery systems (SNEDDS)
  8. Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study
  9. 68Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases
  10. Molecularly Targeted Lanthanide Nanoparticles for Cancer Theranostic Applications
  11. Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer
  12. 99mTc-Labeled Cyclic Peptide Targeting PD-L1 as a Novel Nuclear Imaging Probe
  13. 225Ac-iPSMA-RGD for Alpha-Therapy Dual Targeting of Stromal/Tumor Cell PSMA and Integrins
  14. Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy
  15. Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses
  16. Toxicity Assessment of [177Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
  17. Engineered rHDL Nanoparticles as a Suitable Platform for Theranostic Applications
  18. 131I-C19 Iodide Radioisotope and Synthetic I-C19 Compounds as K-Ras4B–PDE6δ Inhibitors: A Novel Approach against Colorectal Cancer—Biological Characterization, Biokinetics and Dosimetry
  19. [99mTc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities
  20. Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer
  21. IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery
  22. [99mTc]Tc-iFAP Radioligand for SPECT/CT Imaging of the Tumor Microenvironment: Kinetics, Radiation Dosimetry, and Imaging in Patients
  23. 225Ac-rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins
  24. Targeted Endoradiotherapy with Lu2O3-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image
  25. Targeted photodynamic therapy using reconstituted high-density lipoproteins as rhodamine transporters
  26. Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging
  27. Preparation and Dosimetry Assessment of 166Dy2O3/166Ho2O3-iPSMA Nanoparticles for Targeted Hepatocarcinoma Radiotherapy
  28. A Multimodal Theranostic System Prepared from High-Density Lipoprotein Carrier of Doxorubicin and 177Lu
  29. Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications
  30. Preclinical dosimetric studies of 177Lu‐scFvD2B and comparison with 177Lu‐PSMA‐617 and 177Lu‐iPSMA endoradiotherapeutic agents
  31. [68Ga]Ga-iPSMA-Lys3-Bombesin: Biokinetics, dosimetry and first patient PET/CT imaging
  32. Electron transfer reactions in rhodamine: Potential use in photodynamic therapy
  33. Development of 177Lu-DN(C19)-CXCR4 Ligand Nanosystem for Combinatorial Therapy in Pancreatic Cancer
  34. Drug Delivery Systems‐Based Dendrimers and Polymer Micelles for Nuclear Diagnosis and Therapy
  35. Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy
  36. Synthesis, chemical and biochemical characterization of Lu2O3-iPSMA nanoparticles activated by neutron irradiation
  37. Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen
  38. Hybrid (2D/3D) Dosimetry of Radiolabeled Gold Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer
  39. Synthesis and Biochemical Evaluation of Samarium-153 Oxide Nanoparticles Functionalized with iPSMA-Bombesin Heterodimeric Peptide
  40. 99mTc-CXCR4-L for Imaging of the Chemokine-4 Receptor Associated with Brain Tumor Invasiveness: Biokinetics, Radiation Dosimetry, and Proof of Concept in Humans
  41. Synthesis and preclinical evaluation of the 99mTc-/177Lu-CXCR4-L theranostic pair for in vivo chemokine-4 receptor-specific targeting
  42. 177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer
  43. Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis
  44. Synthesis and Evaluation of 177Lu-DOTA-DN(PTX)-BN for Selective and Concomitant Radio and Drug—Therapeutic Effect on Breast Cancer Cells
  45. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer
  46. [99mTc-HYNIC-N-dodecylamide]: a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging
  47. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer
  48. Dual-Targeted Therapy and Molecular Imaging with Radiolabeled Nanoparticles
  49. Preparation and preclinical evaluation of 68Ga-iPSMA-BN as a potential heterodimeric radiotracer for PET-imaging of prostate cancer
  50. In vitro and in vivo synergistic effect of radiotherapy and plasmonic photothermal therapy on the viability of cancer cells using 177Lu–Au-NLS-RGD-Aptamer nanoparticles under laser irradiation
  51. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: synthesis and assessment of the ability to target the prostate specific membrane antigen
  52. Correction to: Preclinical Biokinetic Modelling of Tc-99m Radiophamaceuticals Obtained from Semi-Automatic Image Processing
  53. 99mTc-exendin(9-39)/octreotide
  54. Preparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical
  55. PMM nanoparticles grafted with RGD to detect neovasculature in tumoral process
  56. Synthesis and in vitro evaluation of an antiangiogenic cancer-specific dual-targeting 177Lu-Au-nanoradiopharmaceutical
  57. 99mTc-labeled PSMA inhibitor: Biokinetics and radiation dosimetry in healthy subjects and imaging of prostate cancer tumors in patients
  58. Biodegradable poly(D,L-lactide-co-glycolide)/poly(L-γ-glutamic acid) nanoparticles conjugated to folic acid for targeted delivery of doxorubicin
  59. Preclinical Biokinetic Modelling of Tc-99m Radiophamaceuticals Obtained from Semi-Automatic Image Processing
  60. Clinical translation of a PSMA inhibitor for 99m Tc-based SPECT
  61. Physicochemical behaviour of a dinuclear uranyl complex formed with an octaphosphinoylated para - tert -butylcalix[8]arene. Spectroscopic studies in solution and in the solid state
  62. Fluorescent, Plasmonic, and Radiotherapeutic Properties of the 177Lu–Dendrimer-AuNP–Folate–Bombesin Nanoprobe Located Inside Cancer Cells
  63. Preparation and Characterization of a Tumor-Targeting Dual-Image System Based on Iron Oxide Nanoparticles Functionalized with Folic Acid and Rhodamine
  64. Antibacterial Efficacy of Gold and Silver Nanoparticles Functionalized with the Ubiquicidin (29–41) Antimicrobial Peptide
  65. Hydrogels based on poly(ethylene glycol) as scaffolds for tissue engineering application: biocompatibility assessment and effect of the sterilization process
  66. Improved radiopharmaceutical based on 99mTc-Bombesin–folate for breast tumour imaging
  67. Synthesis and evaluation of Lys1(α,γ-Folate)Lys3(177Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer
  68. 177Lu-Dendrimer Conjugated to Folate and Bombesin with Gold Nanoparticles in the Dendritic Cavity: A Potential Theranostic Radiopharmaceutical
  69. A freeze-dried kit formulation for the preparation of Lys27(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas
  70. Comparative Effect Between Laser and Radiofrequency Heating of RGD-Gold Nanospheres on MCF7 Cell Viability
  71. Two Novel Nanosized Radiolabeled Analogues of Somatostatin for Neuroendocrine Tumor Imaging
  72. Tumoral fibrosis effect on the radiation absorbed dose of 177Lu–Tyr3-octreotate and 177Lu–Tyr3-octreotate conjugated to gold nanoparticles
  73. Preparation of Heterobivalent and Multivalent Radiopharmaceuticals to Target Tumors Over-Expressing Integrins
  74. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging
  75. Molecular Targeting Radiotherapy with Cyclo-RGDfK(C) Peptides Conjugated to 177Lu-Labeled Gold Nanoparticles in Tumor-Bearing Mice
  76. Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
  77. Multifunctional targeted therapy system based on99mTc/177Lu-labeled gold nanoparticles-Tat(49-57)-Lys3-bombesin internalized in nuclei of prostate cancer cells
  78. Design and biological evaluation of 99mTc-N2S2-Tat(49–57)-c(RGDyK): A hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins
  79. Laser Heating of Gold Nanospheres Functionalized with Octreotide:In VitroEffect on HeLa Cell Viability
  80. Engineered Multifunctional RGD-Gold Nanoparticles for the Detection of Tumour-Specific α(ν)β(3) Expression: Chemical Characterisation and Ecotoxicological Risk Assessment
  81. 177Lu‐labeled monomeric, dimeric and multimeric RGD peptides for the therapy of tumors expressing α(ν)β(3) integrins
  82. Multifunctional Targeted Radiotherapy System for Induced Tumours Expressing Gastrin-releasing Peptide Receptors
  83. Development of Specific Radiopharmaceuticals for Infection Imaging by Targeting Infectious Micro-organisms
  84. Cyclization of RGD peptide sequences via the macrocyclic chelator DOTA for integrin imaging
  85. Kit for preparation of multimeric receptor-specific 99mTc-radiopharmaceuticals based on gold nanoparticles
  86. Multimeric System of99mTc-Labeled Gold Nanoparticles Conjugated to c[RGDfK(C)] for Molecular Imaging of Tumor α(v)β(3) Expression
  87. 99mTc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection
  88. Click chemistry for [99mTc(CO)3] labeling of Lys3-bombesin
  89. Lys3-Bombesin Conjugated to99mTc-Labelled Gold Nanoparticles for In Vivo Gastrin Releasing Peptide-Receptor Imaging
  90. Biokinetics of [sup 99m]Tc-labeled gold nanoparticles conjugated to mannose for specific sentinel node detection
  91. Gold nanoparticles conjugated to [Tyr3]Octreotide peptide